Northern Trust Corp Atreca, Inc. Transaction History

Northern Trust Corp

$600 Billion
Q3 2024

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	SELL	$0.88 - $1.22 $4,117 - $5,708	-4,679 Reduced 7.33%	59,168 $57,000
Q1 2023 May 15, 2023	BUY	$0.91 - $1.82 $4,564 - $9,129	5,016 Added 8.53%	63,847 $72,000
Q4 2022 Feb 13, 2023	SELL	$0.78 - $1.68 $3,761 - $8,102	-4,823 Reduced 7.58%	58,831 $47,000
Q3 2022 Nov 14, 2022	BUY	$1.59 - $2.74 $7,668 - $13,215	4,823 Added 8.2%	63,654 $100,000
Q2 2022 Aug 12, 2022	SELL	$1.56 - $3.25 $265,816 - $553,783	-170,395 Reduced 74.33%	58,831 $105,000
Q1 2022 May 13, 2022	SELL	$1.61 - $5.2 $31,955 - $103,209	-19,848 Reduced 7.97%	229,226 $726,000
Q4 2021 Feb 08, 2022	SELL	$2.87 - $6.29 $25,393 - $55,653	-8,848 Reduced 3.43%	249,074 $755,000
Q3 2021 Nov 15, 2021	SELL	$4.91 - $9.07 $55,645 - $102,790	-11,333 Reduced 4.21%	257,922 $1.61 Million
Q2 2021 Aug 13, 2021	SELL	$7.82 - $13.8 $438,287 - $773,448	-56,047 Reduced 17.23%	269,255 $2.29 Million
Q1 2021 May 12, 2021	SELL	$13.0 - $19.34 $259,610 - $386,219	-19,970 Reduced 5.78%	325,302 $4.99 Million
Q4 2020 Feb 11, 2021	SELL	$13.03 - $17.09 $14,658 - $19,226	-1,125 Reduced 0.32%	345,272 $5.58 Million
Q3 2020 Nov 16, 2020	BUY	$12.67 - $23.19 $1.13 Million - $2.08 Million	89,559 Added 34.87%	346,397 $4.84 Million
Q2 2020 Aug 14, 2020	BUY	$12.52 - $23.45 $929,472 - $1.74 Million	74,239 Added 40.66%	256,838 $5.47 Million
Q1 2020 May 14, 2020	BUY	$11.4 - $27.28 $1.21 Million - $2.9 Million	106,208 Added 139.03%	182,599 $3.02 Million
Q4 2019 Feb 14, 2020	SELL	$9.68 - $18.67 $35,535 - $68,537	-3,671 Reduced 4.59%	76,391 $1.18 Million
Q3 2019 Nov 13, 2019	BUY	$10.42 - $22.04 $834,246 - $1.76 Million	80,062 New	80,062 $980,000

Others Institutions Holding BCEL

# of Institutions

Shares Held

30.6K

Call Options Held

Put Options Held

View Full List

About Atreca, Inc.

Ticker BCEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,876,000
Description
Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-10...

More about BCEL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.

Account